Real-World study tests oral diabetes drug in thai patients

NCT ID NCT06507475

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how well oral semaglutide (Rybelsus) works for Thai adults with type 2 diabetes in everyday medical practice. Researchers reviewed medical records of 209 patients over 6 months to measure changes in blood sugar (HbA1c) and body weight. The goal was to see if the drug is effective outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral semaglutide (Rybelsus)
What this could lead to: If successful, this could confirm that oral semaglutide works well in real-world Thai patients, supporting its use for blood sugar and weight control in type 2 diabetes.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It is also limited to a specific population and short duration.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Maharaj Nakorn Chiang Mai Hospital_Nephrology

Chiang Mai, 50200, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.